Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
TB antibody tests: Don’t use them
You may also be interested in...
People In Brief
Relievant Medsystems
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.